Literature DB >> 15684277

Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study.

Michael Steffes1, Patricia Cleary, David Goldstein, Randie Little, Hsiao-Mei Wiedmeyer, Curt Rohlfing, Jack England, Jean Bucksa, Maren Nowicki.   

Abstract

BACKGROUND: Clinical trials require assays that provide consistent results during the course of a study. The hemoglobin A1c (HbA1c) assay, a measure of chronic glycemia, is critical to the study of diabetes control and complications.
METHODS: The Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), required 20 years of consistent HbA1c results, measured by three different ion-exchange HPLC procedures. To maintain and document consistent HbA1c results measured in the DCCT and EDIC Central Biochemistry Laboratory, a backup laboratory used frozen hemolysates as long-term calibrators and a HPLC method with a single lot of Bio-Rex 70 resin.
RESULTS: Over 20 years, long-term quality-control values have remained constant. Four studies of nondiabetic ranges produced nearly identical values [mean (SD), 5.1 (0.5)%, 4.9 (0.3)%, 5.0 (0.4)%, and 5.0 (0.3)%].
CONCLUSION: The overall consistency of the HbA1c assays during the 20-year course of the DCCT and EDIC has been critical in establishing the benefits of intensive therapy and in understanding the relationship between long-term glycemia and the development and progression of the complications of diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15684277      PMCID: PMC2635091          DOI: 10.1373/clinchem.2004.042143

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  20 in total

1.  Approach to maintaining comparability of biochemical data during long-term clinical trials.

Authors:  C A Cull; S E Manley; I M Stratton; H A Neil; I S Ross; R R Holman; R C Turner; D R Matthews
Journal:  Clin Chem       Date:  1997-10       Impact factor: 8.327

Review 2.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

3.  Candidate reference methods for hemoglobin A1c based on peptide mapping.

Authors:  U Kobold; J O Jeppsson; T Dülffer; A Finke; W Hoelzel; K Miedema
Journal:  Clin Chem       Date:  1997-10       Impact factor: 8.327

4.  Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.

Authors: 
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

5.  The national glycohemoglobin standardization program: a five-year progress report.

Authors:  R R Little; C L Rohlfing; H M Wiedmeyer; G L Myers; D B Sacks; D E Goldstein
Journal:  Clin Chem       Date:  2001-11       Impact factor: 8.327

6.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

7.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.

Authors:  David M Nathan; John Lachin; Patricia Cleary; Trevor Orchard; David J Brillon; Jye-Yu Backlund; Daniel H O'Leary; Saul Genuth
Journal:  N Engl J Med       Date:  2003-06-05       Impact factor: 91.245

8.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Authors: 
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

View more
  61 in total

1.  Measurement of HbA1c from stored whole blood samples in the Atherosclerosis Risk in Communities study.

Authors:  Elizabeth Selvin; Josef Coresh; Hong Zhu; Aaron Folsom; Michael W Steffes
Journal:  J Diabetes       Date:  2010-03-15       Impact factor: 4.006

2.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.

Authors:  Ian H de Boer; Wanjie Sun; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Bernard Zinman
Journal:  N Engl J Med       Date:  2011-11-12       Impact factor: 91.245

3.  Relative inaccuracy of the A1cNow in children with type 1 diabetes.

Authors:  Larry Fox; Mariya Dontchev; Katrina Ruedy; Roy Beck; Craig Kollman; Laurel Messer; Julie Coffey; Darrell Wilson; Elizabeth Doyle; William Tamborlane; Michael Steffes
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

4.  Risk factors for urinary incontinence among women with type 1 diabetes: findings from the epidemiology of diabetes interventions and complications study.

Authors:  Aruna V Sarma; Alka Kanaya; Leroy M Nyberg; John W Kusek; Eric Vittinghoff; Brandy Rutledge; Patricia A Cleary; Patricia Gatcomb; Jeanette S Brown
Journal:  Urology       Date:  2009-04-10       Impact factor: 2.649

5.  Insulin therapy, hyperglycemia, and hypertension in type 1 diabetes mellitus.

Authors:  Ian H de Boer; Bryan Kestenbaum; Tessa C Rue; Michael W Steffes; Patricia A Cleary; Mark E Molitch; John M Lachin; Noel S Weiss; John D Brunzell
Journal:  Arch Intern Med       Date:  2008-09-22

6.  Long-term effect of diabetes and its treatment on cognitive function.

Authors:  Alan M Jacobson; Gail Musen; Christopher M Ryan; Nancy Silvers; Patricia Cleary; Barbara Waberski; Amanda Burwood; Katie Weinger; Meg Bayless; William Dahms; Judith Harth
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

7.  Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents.

Authors:  Neil H White; Wanjie Sun; Patricia A Cleary; William V Tamborlane; Ronald P Danis; Dean P Hainsworth; Matthew D Davis
Journal:  Diabetes       Date:  2010-02-11       Impact factor: 9.461

8.  Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study.

Authors:  Stephen K Van Den Eeden; Aruna V Sarma; Brandy N Rutledge; Patricia A Cleary; John W Kusek; Leroy M Nyberg; Kevin T McVary; Hunter Wessells
Journal:  Diabetes Care       Date:  2009-01-26       Impact factor: 19.112

9.  Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort.

Authors:  Paul Enzlin; Raymond Rosen; Markus Wiegel; Jeanette Brown; Hunter Wessells; Patricia Gatcomb; Brandy Rutledge; Ka-Ling Chan; Patricia A Cleary
Journal:  Diabetes Care       Date:  2009-05       Impact factor: 19.112

10.  A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose.

Authors:  Andrew D Paterson; Daryl Waggott; Andrew P Boright; S Mohsen Hosseini; Enqing Shen; Marie-Pierre Sylvestre; Isidro Wong; Bhupinder Bharaj; Patricia A Cleary; John M Lachin; Jennifer E Below; Dan Nicolae; Nancy J Cox; Angelo J Canty; Lei Sun; Shelley B Bull
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.